Anal canal adenocarcinoma
disease diseaseOn this page
Also known as adenocarcinoma arising in anal mucosaadenocarcinoma arising in the anal mucosaadenocarcinoma of anal canaladenocarcinoma of the anal canalanal canal adenocarcinoma (disease)
Summary
Anal canal adenocarcinoma (MONDO:0002735) is a disease. A subtype of anus adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 12
Clinical features
Epidemiology
Prevalence records
23 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.253 | Europe | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.238 | Austria | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.226 | Belgium | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.485 | Bulgaria | Validated |
| Annual incidence | <1 / 1 000 000 | 0.076 | Croatia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.269 | Czech Republic | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.24 | Estonia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.105 | Finland | Validated |
| Annual incidence | <1 / 1 000 000 | 0.09 | France | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.12 | Germany | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.256 | Iceland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.299 | Ireland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.499 | Italy | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.287 | Latvia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.215 | Lithuania | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.144 | Norway | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.217 | Poland | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.406 | Portugal | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.382 | Slovakia | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.343 | Spain | Validated |
Signs & symptoms
Clinical features (HPO)
12 HPO clinical features (Orphanet curated; top 12 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0030439 | Anal canal adenocarcinoma | Obligate (100%) |
| HP:0002025 | Anal stenosis | Very frequent (80-99%) |
| HP:0002027 | Abdominal pain | Very frequent (80-99%) |
| HP:0002584 | Intestinal bleeding | Very frequent (80-99%) |
| HP:0002716 | Lymphadenopathy | Very frequent (80-99%) |
| HP:0002896 | Neoplasm of the liver | Frequent (30-79%) |
| HP:0010622 | Neoplasm of the skeletal system | Frequent (30-79%) |
| HP:0012432 | Chronic fatigue | Frequent (30-79%) |
| HP:0100526 | Neoplasm of the lung | Frequent (30-79%) |
| HP:0002035 | Rectal prolapse | Occasional (5-29%) |
| HP:0100743 | Neoplasm of the rectum | Occasional (5-29%) |
| HP:0200042 | Skin ulcer | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anal canal adenocarcinoma |
| Mondo ID | MONDO:0002735 |
| Orphanet | 424016 |
| DOID | DOID:3692 |
| ICD-11 | 168138050 |
| NCIT | C7471 |
| SNOMED CT | 764845008 |
| UMLS | C1332259 |
| MedGen | 233977 |
| GARD | 0021773 |
| Anatomy (UBERON) | UBERON:0000159 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma arising in anal mucosa · adenocarcinoma arising in the anal mucosa · adenocarcinoma of anal canal · adenocarcinoma of the anal canal · anal canal adenocarcinoma · anal canal adenocarcinoma (disease)
Data availability: 1 HPO phenotype.
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › colorectal adenocarcinoma › rectum adenocarcinoma › anus adenocarcinoma › anal canal adenocarcinoma
Related subtypes (3): anal Paget disease, anal mucinous adenocarcinoma, anal gland adenocarcinoma
Subtypes (1): anal canal Paget disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.